We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BRO:NYSEBrown & Brown, Inc. Analysis

Data as of 2026-03-10 - not real-time

$68.58

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Brown & Brown is trading well beneath its 20‑day, 50‑day and 200‑day moving averages, with a bearish price trend and a relative strength index hovering in the low‑mid‑30s, suggesting continued downside pressure but also a potential oversold condition. The stock is currently near a key support level just above $65 and faces resistance around $74, while volatility over the past month has spiked above 35%, and its beta is markedly low, indicating limited market‑wide correlation.
On the fundamentals side, the company posted robust revenue growth of roughly 36% YoY, healthy gross and operating margins, and strong cash generation that comfortably funds a modest 19% dividend payout. The DCF‑derived fair value exceeds $130, implying an upside of more than 20% versus today’s price, and a recent $250 million accelerated share‑repurchase program adds further price‑support. Analysts are largely neutral with a “hold” consensus, but the recent Mizuho upgrade to Outperform and the company’s low leverage relative to peers reinforce a longer‑term buying case.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below all major moving averages and near technical support
  • Decreasing volume trend dampens short‑term momentum
  • Share‑repurchase program provides a modest floor

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • DCF upside of >20% and forward PE well below industry average
  • Strong cash flow and low payout ratio support dividend sustainability
  • Mizuho’s upgrade and limited AI disruption risk boost confidence

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Consistent revenue growth and solid operating margins
  • Robust balance sheet with manageable debt and ample liquidity
  • Strategic position in insurance brokerage with low beta and defensive exposure

Key Metrics & Analysis

Financial Health

Revenue Growth36.20%
Profit Margin18.29%
P/E Ratio21.7
ROE11.23%
ROA4.24%
Debt/Equity62.98
P/B Ratio1.8
Op. Cash Flow$1.4B
Free Cash Flow$1.4B
Industry P/E17.3

Technical Analysis

TrendBearish
RSI38.0
Support$65.68
Resistance$73.80
MA 20$70.24
MA 50$74.39
MA 200$89.13
MACDBullish
VolumeDecreasing
Fear & Greed Index76.91

Valuation

Fair Value$136.68
Target Price$83.43
Upside/Downside21.65%
GradeUndervalued
TypeBlend
Dividend Yield0.89%

Risk Assessment

Beta0.31
Volatility38.77%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.